UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests in Consolidated Subsidiaries	Redeemable Noncontrolling Interests
Balance at beginning of period at Dec. 31, 2021	$ 1,084.6	$ 1,070.5	$ 1.7	$ (820.3)	$ 237.8	$ 1,659.5	$ (8.2)	$ 14.1	$ 0.2
Balance (in shares) at Dec. 31, 2021			150,753,687	24,151,348
Increase (Decrease) in Stockholders' Equity
Stock options exercised	3.1	3.1			3.1
Stock options exercised (in shares)			118,630
Restricted Stock units vested (in shares)			22,440
Stock based compensation	3.8	3.8			3.8
Shares Repurchased	(105.6)	(105.6)		$ (105.6)
Shares Repurchased (in shares)			(1,603,055)	1,603,055
Cash dividends paid to common shareholders	(7.5)	(7.5)				(7.5)
Formation of Acuity Spatial Genomics Inc.									6.8
Consolidated net (loss) income	62.1	61.6				61.6		0.5
Other comprehensive income (loss)	(9.2)	(8.9)					(8.9)	(0.3)	(0.2)
Balance at end of period at Mar. 31, 2022	1,031.3	1,017.0	$ 1.7	$ (925.9)	244.7	1,713.6	(17.1)	14.3	6.8
Balance (in shares) at Mar. 31, 2022			149,291,702	25,754,403
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.2	0.2			0.2
Stock options exercised (in shares)			14,110
Restricted Stock units vested (in shares)			1,811
Stock based compensation	3.8	3.8			3.8
Shares Repurchased	(60.3)	(60.3)		$ (60.3)
Shares Repurchased (in shares)			(983,741)	983,741
Cash dividends paid to common shareholders	(7.5)	(7.5)				(7.5)
Consolidated net (loss) income	49.9	49.5				49.5		0.4	(0.2)
Other comprehensive income (loss)	(33.0)	(32.2)					(32.2)	(0.8)	(0.3)
Balance at end of period at Jun. 30, 2022	984.4	970.5	$ 1.7	$ (986.2)	248.7	1,755.6	(49.3)	13.9	6.3
Balance (in shares) at Jun. 30, 2022			148,323,882	26,738,144
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.6	0.6			0.6
Stock options exercised (in shares)			30,699
Restricted Stock units vested	(3.1)	(3.1)			(3.1)
Restricted Stock units vested (in shares)			204,951
Stock based compensation	3.9	3.9			3.9
Shares Repurchased	(72.4)	(72.4)		$ (72.4)
Shares Repurchased (in shares)			(1,192,898)	1,192,898
Cash dividends paid to common shareholders	(7.4)	(7.4)				(7.4)
Consolidated net (loss) income	88.6	88.1				88.1		0.5	(0.2)
Acquisition of minority interest	(3.2)	(0.6)				(0.4)	(0.2)	(2.6)
Other comprehensive income (loss)	(43.4)	(42.6)					(42.6)	(0.8)	(0.4)
Balance at end of period at Sep. 30, 2022	948.0	937.0	$ 1.7	$ (1,058.6)	250.1	1,835.9	(92.1)	11.0	5.7
Balance (in shares) at Sep. 30, 2022			147,366,634	27,931,042
Balance at beginning of period at Dec. 31, 2022	1,125.7	1,113.8	$ 1.7	$ (1,085.0)	256.3	1,926.0	14.8	11.9	6.1
Balance (in shares) at Dec. 31, 2022			147,023,144	28,366,442
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.7	0.7			0.7
Stock options exercised (in shares)			34,957
Restricted Stock units vested	(0.1)	(0.1)			(0.1)
Restricted Stock units vested (in shares)			18,463
Stock based compensation	4.1	4.1			4.1
Employee stock purchase plan	0.2	0.2			0.2
Shares Repurchased	(22.3)	(22.3)		$ 22.2	(0.1)
Shares Repurchased (in shares)			(315,318)	315,318
Cash dividends paid to common shareholders	(7.4)	(7.4)				(7.4)
Biognosys acquisition - other shareholders									2.3
Other shareholders of majority-owned acquisitions									3.6
Proceeds from the sale of noncontrolling interests	5.3							5.3
Consolidated net (loss) income	77.5	76.5				76.5		1.0	(0.1)
Other comprehensive income (loss)	15.1	14.8					14.8	0.3	0.1
Balance at end of period at Mar. 31, 2023	1,198.8	1,180.3	$ 1.7	$ (1,107.2)	261.1	1,995.1	29.6	18.5	12.0
Balance (in shares) at Mar. 31, 2023			146,761,246	28,681,760
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.5	0.5			0.5
Stock options exercised (in shares)			26,265
Restricted Stock units vested (in shares)			2,897
Stock based compensation	4.1	4.1			4.1
Employee stock purchase plan	1.8	1.8			1.8
Employee Stock Purchase Plan (in shares)			26,667
Cash dividends paid to common shareholders	(7.4)	(7.4)				(7.4)
Biognosys acquisition - other shareholders									0.2
Loan to noncontrolling interest	(0.3)							(0.3)
Consolidated net (loss) income	58.2	57.1				57.1		1.1	(0.4)
Other comprehensive income (loss)	(5.0)	(5.2)					(5.2)	0.2	0.1
Balance at end of period at Jun. 30, 2023	1,250.7	1,231.2	$ 1.7	$ (1,107.2)	267.5	2,044.8	24.4	19.5	11.9
Balance (in shares) at Jun. 30, 2023			146,817,075	28,681,760
Increase (Decrease) in Stockholders' Equity
Stock options exercised	5.2	5.2			5.2
Stock options exercised (in shares)			137,291
Restricted Stock units vested	(3.2)	(3.2)			(3.2)
Restricted Stock units vested (in shares)			190,408
Stock based compensation	4.6	4.6			4.6
Employee stock purchase plan	0.2	0.2			0.2
Shares Repurchased	(80.3)	80.3		$ 79.7	(0.6)
Shares Repurchased (in shares)			(1,243,461)	1,243,461
Cash dividends paid to common shareholders	(7.4)	(7.4)				(7.4)
Other shareholders of majority-owned acquisitions									6.0
Distributions to noncontrolling interest	(1.5)							(1.5)
Consolidated net (loss) income	89.1	88.1				88.1		1.0	(0.4)
Other comprehensive income (loss)	(30.3)	(29.6)					(29.6)	(0.7)	(0.4)
Balance at end of period at Sep. 30, 2023	$ 1,227.1	$ 1,208.8	$ 1.7	$ (1,186.9)	$ 273.7	$ 2,125.5	$ (5.2)	$ 18.3	$ 17.1
Balance (in shares) at Sep. 30, 2023			145,901,313	29,925,221